Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T cells in relapsed/refractory B-cell lymphoma
NCT02842138Phase 1Unknown
- Sponsor
- Peking University
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zorpocabtagene autoleucel in B cell lymphoma, sponsored by Peking University. Primary endpoint: Number of patients with adverse events at 2 years. Status: unknown.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02842138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842138.